Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects
- 8 February 2020
- journal article
- research article
- Published by Elsevier in Biological Psychiatry
- Vol. 88 (3) , 224-235
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Mental Health (2R25MH071584-11 and Grant No. 2T32MH019961-21A1)
- Translational Neuroscience Research
- National Institute on Aging (5R00AG052604-04)
- Yale University (P30AG021342)
This publication has 72 references indexed in Scilit:
- DNA methylation age of human tissues and cell typesGenome Biology, 2013
- Homelessness in SchizophreniaPsychiatric Clinics of North America, 2012
- Review: Cancer and schizophrenia: is there a paradox?Journal of Psychopharmacology, 2010
- Antipsychotic Drugs Activate the C. elegans Akt Pathway via the DAF-2 Insulin/IGF-1 ReceptorACS Chemical Neuroscience, 2010
- β2-Microglobulin abnormalities in antipsychotic-naïve schizophrenia: Evidence for immune pathogenesisBrain, Behavior, and Immunity, 2009
- Is Schizophrenia a Syndrome of Accelerated Aging?Schizophrenia Bulletin, 2008
- A Systematic Review of Mortality in SchizophreniaArchives of General Psychiatry, 2007
- NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumorsBlood, 2006
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- Higher Natural Killer Cell Activity in Schizophrenic Patients: The Impact of Serum Factors, Medication, and SmokingBrain, Behavior, and Immunity, 2000